Document is current
Any future updates will be listed below
-
Authors
Gersing, Sarah
Schulze, Thea K.
Cagiada, Matteo
Stein, Amelie
Roth, Frederick P.
Lindorff-Larsen, Kresten
Hartmann-Petersen, Rasmus https://orcid.org/0000-0002-4155-7791
-
Funding
Funding for this research was provided by:
Novo Nordisk Fonden (PRISM NNF18OC0033950, PRISM NNF18OC0033950, PRISM NNF18OC0033950, REPIN NNF18OC0033926)
Natur og Univers, Det Frie Forskningsråd (https://doi.org/10.46540/2032-00007B)
National Institutes of Health (Human Genome Research Institute (NIH/NHGRI) Center of Excellence in Genomic Science Initiative (HG010461))
NIH/NHGRI (Impact of Genomic Variation on Function (IGVF) Initiative (HG011989))
Canadian Institutes of Health Research (Foundation Grant)
Novo Nordisk Fonden (ROBUST NF18OC0032608)
Copenhagen University
- License Information
-
More Information
Article History
Received: 30 May 2023
Accepted: 4 April 2024
First Online: 16 April 2024
Declarations
:
: Not applicable.
: Not applicable.
: F.P.R. is a shareholder and advisor for SeqWell, Constantiam, BioSymetrics, and a shareholder of Ranomics, and his lab has received research support from Alnylam, Deep Genomics, Beam Therapeutics, and Biogen Inc. K.L.-L. is a consultant for and holds stock options in Peptone Ltd. The other authors declare that they have no competing interests.
